ANVS ALERT - Nationally Ranked Shareholder Rights Firm Labaton Sucharow Is Investigating Annovis Bio, Inc. for Potential Securities Violations

·1 min read

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ('Annovis') (NYSE:ANVS).

On July 28, 2021, after the market closed, Annovis reported clinical trial data for its Alzheimer's and Parkinson's disease drug Posiphen that failed to show statistical significance in treating patients relative to the placebo. Following this news, Annovis' stock price declined by $65.94 per share, over 60%.

Labaton Sucharow is investigating whether Annovis misled investors regarding the efficacy of Posiphen.

If you currently own stock or options of ANVS and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at labaton.com.

CONTACT:
David J. Schwartz
(800) 321-0476
david@labaton.com

SOURCE: Labaton Sucharow LLP



View source version on accesswire.com:
https://www.accesswire.com/657991/ANVS-ALERT--Nationally-Ranked-Shareholder-Rights-Firm-Labaton-Sucharow-Is-Investigating-Annovis-Bio-Inc-for-Potential-Securities-Violations

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting